Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer
Journal of Clinical Oncology · 10.08.2025 · 43 (23) · 2559-2565
DOI: 10.1200/jco-24-02550 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.08.2025. Verfasst von Barbara Burtness und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Papillomavirus Infections. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
This phase II trial of transoral surgery (TOS) with deintensified postoperative management in human papillomavirus (HPV)–associated oropharynx cancer (OPC) enrolled patients with resectable cT1-2 stage III/IV American Joint Committee on Cancer (AJCC) seventh edition p16+ OPC without matted neck nodes. Those with clear margins, 0-1 + nodes (LN), and no extranodal extension (ENE) were observed (arm A); those with clear margins, 2-4 + LN, or ENE ≤1 mm were randomly assigned to 50 Gy (arm B) or 60 Gy (arm C); and those with involved margins, >4 + LN, or >1 mm ENE received weekly cisplatin and 60-66 Gy (arm D). Among 359 evaluable patients, the 54-month progression-free (PFS) and overall survival (OS) were 90.6% (90% CI, 87.2% to 93.1%) and 95.3% (93.0% to 96.9%), respectively. The 54-month PFS by arm was A 93.2% (79.6% to 97.8%; all four recurrences among N1 patients), B 94.9% (89.7% to 97.5%), C 90.2% (82.7% to 94.6%), and D 85.5% (77.5% to 90.8%). The 54-month OS by arm was A 97.1% (85.7% to 99.4%), B 97.9% (93.5% to 99.3%), C 95.1% (90.1% to 97.6%), and D 92.5% (86.9% to 95.7%). PFS or OS did not differ by primary site or smoking history. TOS and neck dissection with deintensified postoperative management results in outstanding 54-month PFS and OS. Among patients with favorable pathologic characteristics, those with N1 disease are at risk of late recurrence without radiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT.
- ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA.
- Department of Radiation Oncology and Molecular Radiation Sciences. Johns Hopkins University School of Medicine, Baltimore, MD.
- Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA.
- Department of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center.
- Department of Pathology, Mayo Clinic, Rochester, MN.
ORCID-Profile: Barbara Burtness, Yael Flamand, Harry Quon, Ranee Mehra, Chukwuemeka Ikpeazu, Neil D Gross, R Bryan Bell, Miriam N Lango, Luc G Morris, Floyd C Holsinger, Robert L Ferris
Förderung
- NCI NIH HHS
Zitieren
APA
Burtness, B., Flamand, Y., Quon, H., Weinstein, G. S., Mehra, R., Garcia, J. J., Kim, S., O'Malley, B. W., Ozer, E., Ikpeazu, C., Koch, W. M., Gross, N. D., Bell, R. B., Patel, M., Lango, M. N., Morris, L. G., Smith, R., Karakla, D., Richmon, J. D., …, & Ferris, R. L. (2025). Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer. Journal of Clinical Oncology, 43(23), 2559-2565. https://doi.org/10.1200/jco-24-02550
Vancouver
Burtness B, Flamand Y, Quon H, Weinstein GS, Mehra R, Garcia JJ, et al. Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer. Journal of Clinical Oncology. 2025;43(23):2559-2565. doi:10.1200/jco-24-02550
BibTeX
@article{Burtness2025,
author = {Burtness, Barbara and Flamand, Yael and Quon, Harry and Weinstein, Gregory S and Mehra, Ranee and Garcia, Joaquin J and Kim, Seungwon and O'Malley, Bert W and Ozer, Enver and Ikpeazu, Chukwuemeka and Koch, Wayne M and Gross, Neil D and Bell, R Bryan and Patel, Mihir and Lango, Miriam N and Morris, Luc G and Smith, Russell and Karakla, Daniel and Richmon, Jeremy D and Holsinger, Floyd C and Ferris, Robert L},
title = {Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {23},
pages = {2559--2565},
doi = {10.1200/jco-24-02550}
}
EUVIMED